InspireMD Inc (NSPR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $30.13M
Last updated: Nov 17, 2026 at 11:05 AM ET
InspireMD Inc (NSPR) Stock Forecast
Analysts expect InspireMD (NSPR) to earn -$0.45 per share in the fiscal year ending Dec 31, 2026, on revenue of $9.80M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Strong Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.33, inside the Strong Buy band below 1.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 66.7% |
| Buy | 1 | 33.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Strong Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 105.4%.
- Fiscal year ending Dec 31, 2026
- -$0.45
- EPS consensus, revenue $9.80M
- Fiscal year ending Dec 31, 2027
- -$0.48
- EPS consensus, revenue $20.13M
- Next report
- Mar 16, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.45 | -$0.63 to -$0.13 | 3 | $9.80M | $9.40M to $10.28M | 3 |
| Dec 31, 2027 | -$0.48 | -$0.52 to -$0.45 | 3 | $20.13M | $16.02M to $26.27M | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.14 to -$0.12 | 5 | $2.70M | $2.25M to $3.15M | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.74.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.45 | -$0.74 | -$0.74 | -$0.74 | -$0.74 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.48 | -$0.61 | -$0.61 | -$0.61 | -$0.61 | N/A |
Frequently Asked Questions About NSPR
What is the NSPR stock forecast?
Consensus analyst estimates put InspireMD's EPS at -$0.45 for the fiscal year ending Dec 31, 2026, on revenue of $9.80M. The consensus rating from 3 analysts is Strong Buy.
How do analysts rate NSPR stock?
Of 3 analysts covering InspireMD, 2 rate it Strong Buy, 1 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Strong Buy.
What EPS do analysts expect from NSPR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.45, with estimates from -$0.63 to -$0.13 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.48, with estimates from -$0.52 to -$0.45 from 3 analysts.
What revenue do analysts expect from InspireMD next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $9.80M, with estimates from $9.40M to $10.28M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.13M, with estimates from $16.02M to $26.27M.
How many analysts cover NSPR?
3 analysts rate InspireMD stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NSPR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors